Abstract 1049
Background
This study is a pretest-posttest, randomized, controlled experimental study that was intended to analyze the effect of multiple initiatives on beliefs about cervical cancer, health responsibility, and screening participation.
Methods
The group that was addressed were women between 40 and 55 years of age who were at risk of cervical cancer. The study was carried out between March 13 and June 18, 2017 in a primary health care center. The sample for this study included 134 women (experimental group: 64; control group; 67). The 14 weeks of sessions involving the experimental group included group training and delivery of brochures on cervical cancer, training and counseling during home visits, reminder phone calls, and delivery of materials, all aimed to increase motivation to be screened regularly for cervical cancer. The control group maintained their routine practices. To prevent any ethical violations, the group training as well as the brochures, magnets, and mugs that were given to the experimental group before the sessions were provided after the post-tests to the control group as well. The study data were collected using an information form, the Cervical Cancer and Pap-Smear Test Health Belief Model Scale, the Healthy Lifestyle Behaviors Scale II (Health Responsibility), and The Assessment Form for Undergoing Pap-Smear Test. The data were analyzed using dependent groups t test and independent groups t test.
Results
After the multiple interventions, there was a significant difference between the test and control groups’ Health Responsibility, Pap smear benefit and motivation, Pap smear obstacle and health motivation scores (p < 0.05). After multiple interventions, the participation rate of women in the experimental group to cervical cancer screening was found to be 93% and the rate of cervical cancer screening was significantly higher than in the control group (p < 0.05).
Conclusions
In the light of the results of these studies, it may be suggested to conduct studies in factorial design where the effectiveness of different methods to increase participation in cervical cancer screening is evaluated.
Clinical trial identification
NCT03076879, 26 September 2017.
Editorial acknowledgement
Legal entity responsible for the study
Busra Altinel.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3911 - Defining a SUV decrease cut-off in PET/CT response monitoring after one cycle of preoperative breast cancer chemotherapy
Presenter: Marcin Kubeczko
Session: Poster Display session 2
Resources:
Abstract
1849 - Effect of thioredoxin 1 quantity detection to complement the mammography in breast cancer diagnosis
Presenter: Younju Lee
Session: Poster Display session 2
Resources:
Abstract
2221 - Identification of ultralow risk breast cancer patients (probable overdiagnosis)
Presenter: Salvador Gamez Casado
Session: Poster Display session 2
Resources:
Abstract
5291 - Prevalence of Vitamin D3 deficiency among women with early breast cancer receiving chemotherapy in an oncology dayward.
Presenter: Warner Finstad
Session: Poster Display session 2
Resources:
Abstract
4247 - Changes in ER pathway activity score during neoadjuvant letrozole to assess therapy response and predict disease free survival (DFS) in ER positive breast cancer patients
Presenter: Arran Turnbull
Session: Poster Display session 2
Resources:
Abstract
568 - Second primary malignancies in patients with breast cancer.
Presenter: Carlos Erasun Lecuona
Session: Poster Display session 2
Resources:
Abstract
1428 - Phase II randomized trial of neoadjuvant trastuzumab and pertuzumab (TP) with either palbociclib + letrozole (Pal+L) or paclitaxel (Pac) for elderly patients with estrogen receptor & HER2 positive (ER+/HER2+) Breast Cancer (BC) (International Breast Cancer Study Group IBCSG 55-17, TOUCH)
Presenter: Laura Biganzoli
Session: Poster Display session 2
Resources:
Abstract
1479 - Neoadjuvant HER2-targeted therapy with or without immunotherapy with pembrolizumab (neoHIP): an open label randomized phase 2 trial
Presenter: Heather McArthur
Session: Poster Display session 2
Resources:
Abstract
1481 - A randomized phase 2 study of peri-operative ipilimumab, nivolumab and cryoablation versus standard care in women with residual, early stage/resectable, triple negative breast cancer after standard-of-care neoadjuvant chemotherapy
Presenter: Heather McArthur
Session: Poster Display session 2
Resources:
Abstract
4334 - ALEXANDRA/IMpassion030: A phase 3 study of standard adjuvant chemotherapy with or without atezolizumab in early stage triple negative breast cancer.
Presenter: Michail Ignatiadis
Session: Poster Display session 2
Resources:
Abstract